PolyPid Ltd expected to post a loss of 43 cents a share - Earnings Preview

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

Roth MKM Remains a Buy on PolyPid (PYPD)

PolyPid says SHIELD II data show D-PLEX100 doxycycline release lasts up to 32 days

PolyPid starts trading on Frankfurt Stock Exchange under 2PV, adding to Nasdaq listing

PolyPid director Yitzhak Jacobovitz files initial beneficial ownership statement

PolyPid files Form 3 disclosing director Robert Benjamin Stein holdings

PolyPid Begins FDA NDA Submission for D-PLEX₁₀₀ to Prevent Surgical Infections

Wall Street Analysts Are Bullish on Top Healthcare Picks

PolyPid’s Moment Is Here: NDA Submission Begins as a High-Impact Catalyst Stack Takes Shape (NASDAQ: PYPD)

BRIEF-Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA

PolyPid Ltd - U.S. Commercialization Partnership Negotiations for D-Plex₁₀₀ on Track

PolyPid Initiates D-Plex₁₀₀ Nda Submission to the FDA

PolyPid Ltd - Nda Submitted Under FDA Fast Track Designation; Clinical Section Expected Q2 2026

PolyPid files initial beneficial ownership statement; COO-US Ori Warshavsky reports 267 ordinary shares owned directly

PolyPid files initial beneficial ownership statement; director Nir Dror-Darwish reports 14,440 stock options at $2.67

PolyPid Ltd. CFO Jonathan Missulawin files initial beneficial ownership statement

PolyPid Director Joseph BenAmram Files Initial Beneficial Ownership Statement

PolyPid Director Brooke Story Files Initial Beneficial Ownership Statement